Clinical trials: H1N1 Influenza
Seasonal Human Influenza
Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers
The purpose of this phase I trial is to evaluate safety and tolerability of GHB01L1 administered as single dose intranasal aerosol for vaccination against influenza A (H1N1) virus.
- Trial name
- GHBCS-01 (NCT00724997)
- Testing
- GHB01L1
- Where
- Austria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
H1N1 Virus
A Study to Validate a New Oral Fluid/Saliva Antibody Test for Novel H1N1v Influenza
At present influenza immunity can only be reliably confirmed by a blood test. This test is invasive for the patient. This study is intended to validate an oral fluid/saliva antibody test for the variant Swine Influenza H1N1.
- Trial name
- Snuffles (NCT01192958)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Public Health England
Influenza
CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations
The purpose of this study is to see how the body reacts to different strengths of the H1N1 flu shot when it is given with or without an "adjuvant." An adjuvant is a substance that may cause the body to produce more antibodies…
- Trial name
- NCT00964951
- Testing
- AS03, Inactivated H1N1 Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza A
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
The goal of this clinical study is to prove the no less immunogenicity of the Grippol Quadrivalent vaccine compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three identical strains of the…
- Conditions
- Influenza, Influenza A, Influenza, Human, Influenza Type B
- Trial name
- NCT06385821
- Testing
- Grippol Quadrivalent, Grippol Plus
- Where
- 14 sites in Russia
- Volunteers
- 824 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Influenza
Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 2009 (swine flu) vaccine in healthy young children
- Trial name
- NCT00996307
- Testing
- MF59-eH1N1_f
- Where
- 29 sites in United States, Mexico
- Volunteers
- 654 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
H1N1 Influenza Virus, Invasive Solid Tumors
Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors
This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of…
- Trial name
- NCT01031719
- Testing
- adjuvanted A(H1N1) influenza vaccine, non-adjuvanted A(H1N1) influenza vaccine
- Where
- 3 sites in Brazil
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Chiltern Pesquisa Clinica Ltda
Influenza
Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in healthy adult and elderly populations.
- Trial name
- NCT00943631
- Testing
- Inactivated H1N1 Vaccine
- Where
- 3 sites in United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Pandemic Influenza
A/H1N1 Immunogenicity and Safety in Adults
The purpose of the study is to obtain immunogenicity and safety data at different dose levels of an investigational H1N1 pandemic influenza vaccine in healthy adults 18 years of age and older.
- Trial name
- NCT00959465
- Testing
- H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)
- Where
- 5 sites in Austria, Germany
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Novel Influenza A/H1N1
Surveillance for Adverse Events Following Pandemic H1N1 Immunization
Influenza vaccines are continuously modified to adjust to the virus antigenic shifts or drifts, and its safety profile may vary.
- Trial name
- NCT01289418
- Volunteers
- 6,525 people, healthy volunteers welcome
- Sponsor
- PHAC/CIHR Influenza Research Network
Live Attenuated Influenza Vaccine
A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).
The Department of Health has recently announced the implementation of annual vaccination for all those aged 18 years and under, with live attenuated influenza vaccine (LAIV), which is delivered as a nasal spray.
- Trial name
- LAIV Immuno (NCT02143882)
- Testing
- Fluenz
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Public Health England
Influenza
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children.
- Trial name
- NCT00972816
- Testing
- MF59-eH1N1
- Where
- 35 sites in United States, Mexico
- Volunteers
- 1,357 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Human
BPL-1357 Against H1N1 Influenza Virus Challenge
Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it.
- Trial name
- NCT07215858
- Testing
- BPL-1357 IM, BPL-1357 IN
- Where
- 2 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Novartis H1N1 Vaccine in Pregnant Women
The purpose of this study is to evaluate the safety of a 2009 H1N1 influenza vaccine in pregnant women and to determine how their body reacts to different strengths of the vaccine.
- Trial name
- NCT00992719
- Testing
- Inactivated H1N1 Vaccine
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00971425
- Testing
- Pandemrix (GSK investigational influenza GSK2340272A vaccine), Fluarix™
- Where
- 6 sites in Germany
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
The purpose of this study is to characterize the safety, immunogenicity, and relative efficacy of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of age or older.
- Trial name
- NCT00979602
- Testing
- GSK2340274A, GSK2340273A
- Where
- 38 sites in United States, Canada
- Volunteers
- 4,048 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine
Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants
The objective of this study is to describe the safety and immunogenicity of a non-adjuvanted vaccine against pandemic influenza A (H1N1)in patients with chronic and or immunocompromised disease, elderly and pregnants.
- Conditions
- Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine, Immunogenicity of Pandemic Influenza A (H1N1)Vaccine
- Trial name
- NCT01218685
- Testing
- Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS
- Where
- Brazil
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Seasonal Influenza
Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children
The seasonal influenza vaccination program for 2010-2011 will be the first to follow the H1N1 pandemic of 2009. Many children either had the H1N1 infection or the adjuvanted H1N1 vaccine.
- Trial name
- NCT01180621
- Testing
- Fluviral
- Where
- 4 sites in Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Influenza
Drug Use Investigation for Arepanrix® (H1N1)
This post-marketing surveillance study is designed to collect safety information such as post-vaccination adverse events and adverse reactions from recipients of Arepanrix® (H1N1) Intramuscular Injection.
- Trial name
- NCT02069496
- Testing
- Arepanrix®
- Volunteers
- 3,405 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People
Background: Researchers want to know if a certain type of antibody in the blood affects whether people get influenza (the flu). They will study 2 different groups with different levels of anti-HA antibodies and expose them to the…
- Trial name
- NCT01971255
- Testing
- Ca/04/2009/H1N1r Challenge Virus
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A Virus Infection, Swine Flu
A Pilot Study for Collection of Anti-Influenza A Immune Plasma
Background: The influenza A virus can cause infections that lead to fever, cough, muscle aches, diarrhea, and headaches, and can even be fatal in some people.
- Trial name
- NCT00984451
- Testing
- Plasma collection following infection or vaccination with influenza A
- Where
- 12 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)